Antisense Therapeutics Ltd
18Patents
15Active
18Granted
44Portfolio score
Filing activity: Feb 11, 2004 → May 6, 2019 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8623836B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 4 | Active |
| US8759314B2 | Methods for treating multiple sclerosis using antisense oligonucleotides | Chemistry; Metallurgy | 2 | Active |
| US9084770B2 | Modulation of insulin like growth factor I receptor expression in cancer | Chemistry; Metallurgy | 2 | Active |
| US9717778B2 | Combination therapy | Human Necessities | 2 | Active |
| US8299039B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 2 | Expired |
| US8415314B2 | Methods for treating multiple sclerosis using antisense oligonucleotides | Chemistry; Metallurgy | 2 | Active |
| US8765700B2 | Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions | Chemistry; Metallurgy | 1 | Active |
| US7468356B2 | Modulation of insulin like growth factor I receptor expression | Emerging Cross-Sectional Technologies | 1 | Expired |
| US11041156B2 | Mobilizing leukemia cells | Chemistry; Metallurgy | 0 | Active |
| US8217017B2 | Modulation of insulin like growth factor I receptor expression | Emerging Cross-Sectional Technologies | 0 | Active |
| US11976281B2 | Therapeutic uses and methods | Chemistry; Metallurgy | 0 | Active |
| US9821034B2 | Combination therapy | Human Necessities | 0 | Active |
| US7846906B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 0 | Expired |
| US8637484B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 0 | Active |
| US9988635B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 0 | Active |
| US9885048B2 | Method for reducing circulating leukocytes in a human subject | Chemistry; Metallurgy | 0 | Active |
| US11891606B2 | Methods for treating multiple sclerosis using antisense oligonucleotides | Chemistry; Metallurgy | 0 | Active |
| US9371530B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.